A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen()()

OBJECTIVES: To evaluate contraceptive effectiveness and safety of oral drospirenone 4 mg 24/4-day regimen in the United States. STUDY DESIGN: We performed a prospective, single-arm, multicenter phase 3 trial in sexually active women for up to thirteen 28-day treatment cycles. Primary outcome was the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Contracept X
Asıl Yazarlar: Kimble, Thomas, Burke, Anne E., Barnhart, Kurt T., Archer, David F., Colli, Enrico, Westhoff, Carolyn L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286157/
https://ncbi.nlm.nih.gov/pubmed/32550535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conx.2020.100020
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller